Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: Effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score

Journal of Invasive Cardiology

Volumn 24, Issue 3, 2012, Pages 84-89

  Hermanides, Renicus S ^a   Ottervanger, Jan Paul ^a   Ten Berg, Jurrien M ^b   Gosselink, A T Marcel ^a   Van Houwelingen, Gert ^c   Dambrink, Jan Henk E ^a   Stella, Pieter R ^d   Hamm, Christian ^e   Van Hof, Arnoud W J ^a  

^a ISALA HOSPITAL   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e KERCKHOFF HEART CENTER   (Germany)

Author keywords

bleeding; CRUSADE bleeding score; glycoprotein IIb IIIa inhibitors; high dose tirofiban; primary PCI; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PLACEBO; TIROFIBAN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLEEDING; CORONARY ARTERY BYPASS GRAFT; DEATH; DRUG EFFECT; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; EMERGENCY CARE; FEMALE; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME; TYROSINE;

EID: 84858399786     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Van 't Hof AWJ, Ten Berg JM, Heestermans AA, et al. Prehospital initiation of tiro-fban in patients with ST-elevation myocardial infarction undergoing primary angio-plasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372(9638):537-546.
2. Ten Berg JM, van 't Hof AWJ, Dill T, et al; Ongoing Tirofban In Myocardial infarction Evaluation (On-TIME) 2 study group. Effect of early, pre-hospital initiation of high-bolus dose tirofban in patients with ST-segment elevation myocardial infarction on short and long-term clinical outcome. J Am Coll Cardiol. 2010;55(22):2446-2455.
3. Hermanides RS, Ottervanger J P, Dambrink JHE, et al. Risk of bleeding after pre-hos-pital administration of high dose tirofban for ST-elevation myocardial infarction. Int J Cardiol. 2010 Dec 29 (Epub ahead of print).
4. Kinnaird TD, Satbile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930-935. (Pubitemid 37214804)
5. Rao S V, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200-1206. (Pubitemid 41505393)
6. Eikelboom J W, Metha SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-782. (Pubitemid 44268228)
7. Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol. 2007;100(9):1364-1369. (Pubitemid 47576015)
8. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49(12):1362-1368. (Pubitemid 46476844)
9. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51(7):690-697. (Pubitemid 351221218)
10. Van 't Hof AWJ, Hamm C, Rasoul S, et al, on behalf of the On-TIME 2 investigators. Ongoing tirofban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention. 2007;3(3):371-380.
11. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fbrinogen and the f-brinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11(1):1-11. (Pubitemid 18029027)
12. Cockgroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
13. Subherwal S, Bach RG, Chen Ay, et al. Baseline risk of major bleeding in non-ST elevation myocardial infarction. Circulation. 2009;119(14):1873-1882.
14. Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood fow conditions. J Am Coll Cardiol. 2004;44(2):316-323. (Pubitemid 38950589)
15. Montalescot G, Barragan P, Wittenberg O, et al; the ADMIRAL investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344(25):1895-1903. (Pubitemid 32553358)
16. Ortolani P, Marzocchi A, Marrozzini C, et al. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous coronary interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J. 2009;30(1):33-43.
17. Huber K, Holmes Jr DR, Van't Hof AWJ, et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J. 2010;31(14):1708-1716.
18. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330(14):956-961.
19. ESPRIT investigators. Enhanced suppression of the platelet IIb/IIIa receptor with integrillin therapy. Novel dosing regimen of eptifbatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356(9247):2037-2044.
20. Ellis SG, Tendera M, de Belder MA, et al; FINESSE investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358(21):2205-2217. (Pubitemid 351724450)
21. Stone G W, Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI trial investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218-2230. (Pubitemid 351724451)
22. Mehran R, Lansky AL, Witzenbichler B, et al; HORIZONS-AMI trial investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374(9696):1149-1159.
23. Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glyco-protein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853-863. (Pubitemid 37430344)
24. Spencer FA, Moscucci M, Granger GB, et al; GRACE investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007;116(24):2793-2801. (Pubitemid 350291221)
25. Wang TY, Xiao L, Alexander K P, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation. 2008;118(21):2139-2145.
26. Rao S V, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292(13):1555-1562. (Pubitemid 39314961)
27. Rao SV, Eikelboom J, Steg PG, et al; Academic Bleeding Consensus Multidisciplinary Working Group. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary working group. Am Heart J. 2009;158(6):881-886.
28. Verheugt FW, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and infu-ence of antithrombotic therapy on acces and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4(2):191-197.
29. Alexander K P, Chen AY, Roe Mt, et al; CRUSADE investigators. Excess dosing of an-tiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294(24):3108-3116. (Pubitemid 43016802)
30. Abu-assi E, Gracia-Acuna JM, Ferreira-Gonzalez I, et al. Evaluating the performance of the can rapid risk stratifcation of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST segment elevation acute myocardial infarction. Circulation. 2010;121(22):2419-2426.
31. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55(23):2556-2566.
32. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myo-cardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium Early II trial substudy. Circulation. 2000;102(17):2031-2037.